Lipoprotein (a) levels and apolipoprotein (a) isoform size in @entity1 with XXXX : effect of treatment with @entity1955 .

@entity1 @entity1375 @entity3208 @entity2299 @entity1955 @entity3452 @entity741 @entity214 @entity1374
The increased risk for @entity741 ( @entity741 ) associated with @entity1375 ( @entity1375 ) has been partly attributed to @entity2299 . There is limited information on the effect of @entity1375 on lipoprotein (a) [ @entity3452 ], which is considered a significant predictor of @entity741 . Serum @entity3452 levels are predominantly regulated by apolipoprotein [apo(a)] gene polymorphisms. The aim of our study was to evaluate the @entity3452 levels and apo(a) phenotypes in @entity1 with @entity1375 compared to healthy controls as well as the influence of @entity1955 substitution therapy on @entity3452 values in relation to the apo(a) isoform size. @entity3452 levels were measured in 69 @entity1 with @entity1375 before and after restoration of a euthyroid state and in 83 age- and gender-matched healthy controls. Apo(a) isoform size was determined by @entity3208 ( @entity214 ) agarose gel electrophoresis followed by immunoblotting and development via chemiluminescence. @entity1 with @entity1375 exhibited increased @entity3452 levels compared to controls (median value 10.6 mg/dL vs. 6.0 mg/dL, p = 0.003]), but this was not because of differences in the frequencies of apo(a) phenotypes. There was no association between thyrotropin (TSH) and @entity3452 levels in @entity1 with @entity1375 . In subjects with either low (LMW; 25 @entity1 and 28 controls) or high (HMW; 44 @entity1 and 55 controls) molecular weight apo(a) isoforms, @entity3452 concentrations were higher in @entity1 than in the control group (median values 26.9 mg/dL vs. 21.8 mg/dL, p = 0.02 for LMW, and 6.0 mg/dL versus 3.3 mg/dL, p < 0.001 for HMW). @entity1955 treatment resulted in an overall reduction of @entity3452 levels (10.6 mg/dL baseline vs. 8.9 mg/dL posttreatment, p = 0.008]). This effect was mainly evident in @entity1 with LMW apo(a) isoforms associated with high baseline @entity3452 concentrations (median values 26.9 mg/dL vs. 23.2 mg/dL pretreatment and posttreatment, respectively; p = 0.03). In conclusion, even though a causal effect of @entity1374 on @entity3452 was not clearly demonstrated in @entity1 with @entity1375 , @entity1955 treatment is beneficial, especially in @entity1 with increased baseline @entity3452 levels and LMW apo(a) isoforms.
